(:VVUS)

Dec 11, 2020 04:49 pm ET
VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization
VIVUS, Inc. (the “Company”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on its Second Amended Joint Prepackaged Chapter 11...
Nov 13, 2020 08:30 pm ET
VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date
On November 10, 2020, VIVUS, Inc. (the “Company”), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (as may be amended, modified, or...
Jul 07, 2020 04:49 pm ET
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of...
Jun 02, 2020 07:30 am ET
VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of...
May 06, 2020 04:05 pm ET
VIVUS Reports First Quarter 2020 Financial Results
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our ability to respond quickly to the COVID-19 pandemic by successfully...
May 01, 2020 08:40 am ET
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020. The Company will host a conference call beginning at 4:30...
May 01, 2020 08:35 am ET
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of  approximately $170.1 million of the Company’s Convertible...
Apr 03, 2020 03:00 pm ET
VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per share...
Apr 03, 2020 08:00 am ET
VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules
PLANO, Texas, April 3, 2020 /PRNewswire/ -- VitalTech, a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc, a publicly held biopharmaceutical company (Nasdaq: VVUS). Leveraging VitalTech's industry-leading virtual care platform and comprehensive medical device product line, VIVUS plans to rapidly accelerate the launch of its telemedicine, virtual care and remote patient monitoring capabilities.
Apr 01, 2020 09:02 am ET
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the...
Mar 31, 2020 07:30 am ET
VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the accelerated launch of the telemedicine and remote monitoring modules of the VIVUS Health Platform. Participating physicians will be able to use the VIVUS...
Mar 03, 2020 04:05 pm ET
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter and fiscal year ended December 31, 2019 and provided a business update. “Fiscal year 2019 represents our first full year of...
Mar 02, 2020 07:30 am ET
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of patient enrollment in a Phase 4 clinical study designed to evaluate the safety and efficacy of Qsymia® (phentermine and topiramate...
Feb 19, 2020 07:30 am ET
VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen, has launched Qsymia (phentermine and topiramate extended-release) in the Republic of Korea.   “We believe that...
Feb 18, 2020 07:30 am ET
VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on Tuesday, March 3, 2020. The company will host a conference call with...
Feb 05, 2020 07:30 am ET
VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE® (pancrelipase)...
Jan 07, 2020 07:30 am ET
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company, today announced the publication of a new study from the Toolbox Trial (NCT01922934), a real-world clinical trial conducted in urban safety-net primary care clinics offering patients a...
Jan 02, 2020 07:30 am ET
VIVUS to Present at Biotech Showcase on January 13, 2020
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will present at the Biotech Showcase™ 2020 on Monday, January 13, 2020 at 3:30 pm PT/6:30pm ET. The conference will be...
Dec 31, 2019 07:30 am ET
VIVUS Adopts Stockholder Rights Plan
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in...
Dec 18, 2019 07:30 am ET
VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the results of a pharmacokinetic (PK) and pharmacodynamic (PD) study (NCT02714062) demonstrating that Qsymia® (phentermine and topiramate extended-release)...
Nov 25, 2019 07:30 am ET
VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the Piper Jaffray 31st Annual Healthcare Conference at 1:10 P.M. ET on Tuesday, December 3,...
Nov 20, 2019 07:30 am ET
New Clinical Data Demonstrate VIVUS’ Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the results of a clinical study (NCT02553824) demonstrating that patients with binge-eating disorder (BED) or bulimia nervosa (BN) receiving Qsymia...
Nov 05, 2019 04:05 pm ET
VIVUS Reports Third Quarter 2019 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
Oct 28, 2019 07:30 am ET
VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of Directors and all of its committees in order to increase their focus on other personal...
Oct 22, 2019 07:30 am ET
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on Tuesday, November 5, 2019. The company will host a conference call beginning at...
Oct 21, 2019 07:30 am ET
VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will participate in a panel discussion at the Cleveland Clinic 2019 Medical Innovation Summit, which is taking place...
Oct 07, 2019 07:30 am ET
VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland (the “Concerned Member States”) have accepted the Marketing...
Oct 03, 2019 07:30 am ET
VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it has paid down $48.6 million of its Senior Secured Notes due 2024.  This debt reduction will result in savings of $10.5 million due to a reduction in...
Aug 28, 2019 07:30 am ET
VIVUS to Present at Upcoming Conferences
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the following conferences: RHK Capital 4th Annual Disruptive Growth Conference hosted by...
Aug 27, 2019 07:30 am ET
VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019
VIVUS, Inc. (Nasdaq: VVUS; the “Company”) today announced that Santosh T. Varghese, MD, Chief Medical Officer at VIVUS, will present at the 2019 International Congress on Obesity and MEtabolic Syndrome (ICOMES) & Asia-Oceania Conference on Obesity...
Aug 20, 2019 09:31 am ET
Thinking about buying stock in Apache, CNH Industrial, Home Depot, Ibio, or Vivus?
NEW YORK, Aug. 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APA, CNHI, HD, IBIO, and VVUS.
Aug 20, 2019 07:30 am ET
New Pilot Clinical Study Results Demonstrate that Addition of VIVUS’ Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone
VIVUS, Inc. (Nasdaq: VVUS; the “Company”) today announced the results of a pilot clinical study demonstrating that patients receiving Qsymia (phentermine and topiramate extended-release (ER)) capsules CIV before and after laparoscopic sleeve...
Aug 06, 2019 04:05 pm ET
VIVUS Reports Second Quarter 2019 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
Aug 05, 2019 07:30 am ET
VIVUS Announces Approval of Qsymia® in the Republic of Korea
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen, has obtained marketing approval for Qsymia (phentermine and topiramate extended-release) from the South Korea...
Jul 23, 2019 07:30 am ET
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2019 after the market close on Tuesday, August 6, 2019. The company will host a conference call beginning at...
Jun 26, 2019 04:05 pm ET
VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced an amendment to its manufacturing and supply agreement with Nordmark Arzneimittel GmbH & Co. KG (“Nordmark”) for PANCREAZE® (pancrelipase) Delayed Release Capsules....
Jun 11, 2019 07:30 am ET
VIVUS Reduces Barrier to Achieving Healthy Weight Goals With Launch of Online Platform to Purchase Qsymia®
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the launch of an e-medicine platform that will enable patients with a prescription for Qsymia® (phentermine and topiramate extended-release) capsules CIV to...
May 28, 2019 07:30 am ET
VIVUS Initiates Phase Four Safety and Efficacy Study of Qsymia® in Obese Adolescents
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that the first patient has been enrolled in a Phase four clinical study designed to evaluate the safety and efficacy of Qsymia® (phentermine and topiramate...
May 15, 2019 07:53 am ET
VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc., today announced a partnership to facilitate access to PANCREAZE® (pancrelipase) Delayed Release Capsules for uninsured or underinsured patients...
Apr 30, 2019 04:05 pm ET
VIVUS Reports First Quarter 2019 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
Apr 16, 2019 07:30 am ET
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019 after the market close on Tuesday, April 30, 2019. The company will host a conference call beginning at...
Mar 14, 2019 07:30 am ET
VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction
CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. (NASDAQ: VVUS; the "Company"), a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile dysfunction (ED). The product will be marketed in the Russian Federation under the brand name RAZATUS.
Feb 26, 2019 04:05 pm ET
VIVUS Reports Fourth Quarter 2018 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
Feb 13, 2019 07:30 am ET
VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and full year of 2018 after the market close on Tuesday, February 26, 2019. The company will host a conference...
Feb 04, 2019 04:00 pm ET
VIVUS Announces Date of 2019 Annual Meeting
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”) on June 5, 2019. Because the 2019 Annual Meeting will be held...
Jan 14, 2019 07:30 am ET
Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that results from a new study evaluating the cardiovascular safety of Qsymia® (phentermine and topiramate extended-release) capsules CIV will be published in...
Dec 27, 2018 07:30 am ET
VIVUS to Present at Biotech Showcase on January 9, 2019
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that...
Nov 15, 2018 08:25 am ET
New Research Coverage Highlights CommVault, Dawson Geophysical, RF Industries, Hennessy Advisors, VIVUS, and Semiconductor Manufacturing International — Consolidated Revenues, Company Growth, and Expe
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CommVault Systems, Inc. (NASDAQ:CVLT), Dawson Geophysical Company...
Nov 01, 2018 04:10 pm ET
VIVUS Reports Third Quarter 2018 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
Oct 29, 2018 07:30 am ET
VIVUS Adds Two New Members to the Board of Directors
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that Karen Ferrell and Edward A. Kangas have been appointed to VIVUS’ board of directors. With these appointments, VIVUS’ board of directors expands to nine...
Oct 26, 2018 07:30 am ET
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2018 after the market close on Thursday, November 1, 2018. The company will host a conference call beginning...
Oct 10, 2018 07:30 am ET
VIVUS to Present at the BIO Investor Forum on October 17, 2018
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that...
Sep 26, 2018 07:30 am ET
VIVUS Regains Compliance with Nasdaq Listing Requirements
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it has regained full compliance with Nasdaq...
Sep 24, 2018 07:30 am ET
VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up
VIVUS, Inc., (NASDAQ: VVUS), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it will make a presentation at the Fourth Annual Robins Equity...
Sep 21, 2018 07:30 am ET
VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation (CFF) in its CF Climb fundraising event. This support includes financial...
Sep 10, 2018 07:30 am ET
VIVUS Announces 1-for-10 Reverse Stock Split
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock split. Effective September 10, 2018, the Company will enact a 1-for-10 reverse stock split of its...
Aug 27, 2018 07:30 am ET
VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia®
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a retrospective analysis evaluating the cardiovascular safety of Qsymia® (phentermine and topiramate extended-release) capsules CIV.  Results...
Aug 22, 2018 07:30 am ET
VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that...
Aug 07, 2018 04:05 pm ET
VIVUS Reports Second Quarter 2018 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
Aug 06, 2018 07:30 am ET
VIVUS Appoints Kenneth Suh as President
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President.  Previously, Mr. Suh was President and CEO of Willow Biopharma Inc., a wholly-owned subsidiary of...
Jul 31, 2018 07:30 am ET
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018
VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August 7, 2018. The company will host a conference call beginning...
Jul 10, 2018 07:30 am ET
VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced positive preliminary results from a Phase 1 clinical study evaluating the pharmacokinetic (PK) profile of its VI-0106 in healthy volunteers.  VIVUS is...
Jun 11, 2018 07:30 am ET
VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S. and Canadian...
May 08, 2018 04:05 pm ET
VIVUS Reports First Quarter 2018 Financial Results
VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial...
May 04, 2018 04:05 pm ET
VIVUS Announces Date of 2018 Annual Meeting
VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”) on September 7, 2018.  Because the 2018 Annual Meeting will be...
May 01, 2018 07:05 am ET
VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®
Attains key milestone under strategic focus on building a broad portfolio of cash flow-generating products
May 01, 2018 07:00 am ET
VIVUS Restructures Debt and Gains Access to New Capital
Athyrium Capital Management partners with VIVUS to support next growth phase
Apr 30, 2018 04:20 pm ET
VIVUS Strengthens Executive Leadership Team
VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company, today announced the addition of three executives to the Company's senior leadership team. John Amos has joined as the Company's new Chief Executive Officer and a new member of...
Apr 25, 2018 04:05 pm ET
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2018 after the market close on Tuesday, May 8, 2018. The company will host a conference call beginning at 4:30...
Mar 13, 2018 04:05 pm ET
VIVUS Reports Fourth Quarter 2017 Financial Results
VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results...
Dec 26, 2017 04:05 pm ET
VIVUS Announces Change in Leadership
VIVUS, Inc. (NASDAQ: VVUS) today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief executive officer and a member of the board of directors effective December 31, 2017 and become a strategic...
Nov 07, 2017 04:05 pm ET
VIVUS Reports Third Quarter 2017 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results...
Nov 02, 2017 07:00 am ET
VIVUS Completes Tacrolimus Pre-IND Meeting With FDA
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that it held a...
Oct 31, 2017 08:00 am ET
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2017 after the market close on Tuesday, November 7, 2017. The company will host a conference call beginning at...
Sep 06, 2017 04:05 pm ET
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that the...
Sep 05, 2017 08:00 am ET
VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd, today announced an agreement under which Alvogen will market Qsymia® (phentermine and topiramate extended-release) in the Republic of Korea for the treatment of chronic weight...
Aug 30, 2017 04:05 pm ET
VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) resolving patent litigation related to Qsymia® (phentermine and...
Aug 22, 2017 08:00 am ET
VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that Seth H. Z....
Aug 03, 2017 04:15 pm ET
VIVUS Reports Second Quarter 2017 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results...
Jul 05, 2017 04:15 pm ET
VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV. The litigation, which has been pending in the U.S. District Court for the District of New Jersey since 2014, resulted from the submission by Actavis of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market generic versions of Qsymia. The settlement agreement permits Actavis to begin selling a generic
May 24, 2017 04:15 pm ET
Thomas B. King Joins VIVUS' Board of Directors
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that Thomas B. King has been appointed to VIVUS' board of directors. Mr. King's nearly 40 years of pharmaceutical experience ranges from large to development-stage pharmaceutical companies....
May 03, 2017 04:10 pm ET
VIVUS Reports 2017 First Quarter Financial Results
VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today reported its...
Apr 25, 2017 08:00 am ET
VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2017 after the NASDAQ Market closes on Wednesday, May 3, 2017. The company will conduct a conference call and an...
Mar 27, 2017 08:30 am ET
VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that it reached an agreement with Sanofi to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia, to...
Mar 08, 2017 04:10 pm ET
VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs in human health, today reported its financial results for the quarter and year...
Feb 28, 2017 08:00 am ET
VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2016 after the NASDAQ Market closes on Wednesday, March 8, 2017. The company will conduct a conference call and...
Jan 09, 2017 09:00 am ET
VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
VIVUS, Inc. (NASDAQ: VVUS) and Selten Pharma, Inc., announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary Arterial Hypertension...
Nov 09, 2016 04:10 pm ET
VIVUS Reports 2016 Third Quarter Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its...
Oct 26, 2016 05:00 pm ET
VIVUS Announces Date of 2016 Third Quarter Business Update and Financial Results Teleconference
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2016 after the NASDAQ Market closes on Wednesday, November 9, 2016. The company will conduct a conference call...
Oct 03, 2016 08:30 am ET
VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to STENDRA
VIVUS, Inc. (NASDAQ: VVUS) ("VIVUS") and Metuchen Pharmaceuticals LLC ("Metuchen") today announced an agreement providing Metuchen a fully-paid, perpetual license for exclusive rights to commercialize STENDRA® (avanafil) in the U.S., Canada, South...
Aug 29, 2016 04:30 pm ET
VIVUS Extends Return Date of STENDRA Commercial Rights
VIVUS, Inc. (NASDAQ: VVUS) ("VIVUS") and Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International plc ("Auxilium"), today announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA®...
Aug 04, 2016 04:15 pm ET
VIVUS Reports 2016 Second Quarter Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (The "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its...
Jul 27, 2016 04:15 pm ET
VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero.The lawsuit was filed in response...
Jul 26, 2016 04:15 pm ET
VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2016 after the NASDAQ Market closes on Thursday, August 4, 2016. The company will conduct a conference call and...
Jul 21, 2016 06:01 pm ET
VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
VIVUS, Inc. (NASDAQ: VVUS) today announced that the United States District Court for the District of New Jersey has issued a claim construction (Markman) ruling governing patent litigation brought by VIVUS against Actavis Laboratories FL, Inc.,...
Jun 30, 2016 04:15 pm ET
VIVUS to Extend Return Date of STENDRA Commercial Rights
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced an extension of the termination date of...
May 17, 2016 12:31 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
NEW YORK, May 17, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
May 16, 2016 01:53 pm ET
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, May 16, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015.  VIVUS's stock price closed at $1.16 per share on May 13, 2016.
May 03, 2016 04:05 pm ET
Vivus Reports 2016 First Quarter Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its...
Apr 19, 2016 06:00 pm ET
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an...
Mar 09, 2016 04:15 pm ET
VIVUS Reports Fourth Quarter and Year-End 2015 Financial Results
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its...
Feb 29, 2016 08:30 am ET
VIVUS Announces Date of Fourth Quarter 2015 Update and Financial Results Teleconference
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2015 after the NASDAQ Market closes on Wednesday, March 9, 2016. The company will conduct a conference call and an...
Dec 29, 2015 09:00 am ET
A New Take On New Year's And Chronic Weight Management: Smart Changes™ Program Combines Positive Lifestyle Changes With Prescription Medication For Weight Loss
MOUNTAIN VIEW, Calif., Dec. 29, 2015 /PRNewswire/ -- When it comes to New Year's weight loss resolutions and chronic weight management, the best laid plans don't always yield success. A new national online survey among obese or overweight American adultsi shows that over-the-counter (OTC) products and plans are a big part of the problem, and that it is very difficult for people to change their lifestyles. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.